Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions.
Identifieur interne : 004D00 ( PubMed/Checkpoint ); précédent : 004C99; suivant : 004D01Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions.
Auteurs : B C Vrouenraets [Pays-Bas] ; J M Klaase ; B B Kroon ; B N Van Geel ; A M Eggermont ; H R FranklinSource :
- Archives of surgery (Chicago, Ill. : 1960) [ 0004-0010 ] ; 1995.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Amyotrophie (), Femelle, Humains, Hypersensibilité médicamenteuse, Lymphoedème (), Melphalan (effets indésirables), Melphalan (usage thérapeutique), Membres, Morbidité, Mâle, Mélanome (traitement médicamenteux), Perfusion régionale de chimiothérapie anticancéreuse, Sujet âgé, Sujet âgé de 80 ans ou plus, Tumeurs cutanées (traitement médicamenteux).
- MESH :
- effets indésirables : Melphalan.
- traitement médicamenteux : Mélanome, Tumeurs cutanées.
- usage thérapeutique : Melphalan.
- Adulte, Adulte d'âge moyen, Amyotrophie, Femelle, Humains, Hypersensibilité médicamenteuse, Lymphoedème, Membres, Morbidité, Mâle, Perfusion régionale de chimiothérapie anticancéreuse, Sujet âgé, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Chemotherapy, Cancer, Regional Perfusion, Drug Hypersensitivity, Extremities, Female, Humans, Lymphedema (chemically induced), Male, Melanoma (drug therapy), Melphalan (adverse effects), Melphalan (therapeutic use), Middle Aged, Morbidity, Muscular Atrophy (chemically induced), Skin Neoplasms (drug therapy).
- MESH :
- chemical , adverse effects : Melphalan.
- chemically induced : Lymphedema, Muscular Atrophy.
- drug therapy : Melanoma, Skin Neoplasms.
- chemical , therapeutic use : Melphalan.
- Adult, Aged, Aged, 80 and over, Chemotherapy, Cancer, Regional Perfusion, Drug Hypersensitivity, Extremities, Female, Humans, Male, Middle Aged, Morbidity.
Abstract
To determine the influence of acute regional toxic reactions on the incidence and characteristics of long-term morbidity after regional isolated perfusion with melphalan.
PubMed: 7802575
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:7802575Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions.</title><author><name sortKey="Vrouenraets, B C" sort="Vrouenraets, B C" uniqKey="Vrouenraets B" first="B C" last="Vrouenraets">B C Vrouenraets</name><affiliation wicri:level="3"><nlm:affiliation>Department of Surgery, The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Amsterdam.</nlm:affiliation><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName><wicri:orgArea>Department of Surgery, The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis)</wicri:orgArea></affiliation></author><author><name sortKey="Klaase, J M" sort="Klaase, J M" uniqKey="Klaase J" first="J M" last="Klaase">J M Klaase</name></author><author><name sortKey="Kroon, B B" sort="Kroon, B B" uniqKey="Kroon B" first="B B" last="Kroon">B B Kroon</name></author><author><name sortKey="Van Geel, B N" sort="Van Geel, B N" uniqKey="Van Geel B" first="B N" last="Van Geel">B N Van Geel</name></author><author><name sortKey="Eggermont, A M" sort="Eggermont, A M" uniqKey="Eggermont A" first="A M" last="Eggermont">A M Eggermont</name></author><author><name sortKey="Franklin, H R" sort="Franklin, H R" uniqKey="Franklin H" first="H R" last="Franklin">H R Franklin</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1995">1995</date><idno type="RBID">pubmed:7802575</idno><idno type="pmid">7802575</idno><idno type="wicri:Area/PubMed/Corpus">005445</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005445</idno><idno type="wicri:Area/PubMed/Curation">005445</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005445</idno><idno type="wicri:Area/PubMed/Checkpoint">005445</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005445</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions.</title><author><name sortKey="Vrouenraets, B C" sort="Vrouenraets, B C" uniqKey="Vrouenraets B" first="B C" last="Vrouenraets">B C Vrouenraets</name><affiliation wicri:level="3"><nlm:affiliation>Department of Surgery, The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Amsterdam.</nlm:affiliation><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName><wicri:orgArea>Department of Surgery, The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis)</wicri:orgArea></affiliation></author><author><name sortKey="Klaase, J M" sort="Klaase, J M" uniqKey="Klaase J" first="J M" last="Klaase">J M Klaase</name></author><author><name sortKey="Kroon, B B" sort="Kroon, B B" uniqKey="Kroon B" first="B B" last="Kroon">B B Kroon</name></author><author><name sortKey="Van Geel, B N" sort="Van Geel, B N" uniqKey="Van Geel B" first="B N" last="Van Geel">B N Van Geel</name></author><author><name sortKey="Eggermont, A M" sort="Eggermont, A M" uniqKey="Eggermont A" first="A M" last="Eggermont">A M Eggermont</name></author><author><name sortKey="Franklin, H R" sort="Franklin, H R" uniqKey="Franklin H" first="H R" last="Franklin">H R Franklin</name></author></analytic><series><title level="j">Archives of surgery (Chicago, Ill. : 1960)</title><idno type="ISSN">0004-0010</idno><imprint><date when="1995" type="published">1995</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Chemotherapy, Cancer, Regional Perfusion</term><term>Drug Hypersensitivity</term><term>Extremities</term><term>Female</term><term>Humans</term><term>Lymphedema (chemically induced)</term><term>Male</term><term>Melanoma (drug therapy)</term><term>Melphalan (adverse effects)</term><term>Melphalan (therapeutic use)</term><term>Middle Aged</term><term>Morbidity</term><term>Muscular Atrophy (chemically induced)</term><term>Skin Neoplasms (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Amyotrophie ()</term><term>Femelle</term><term>Humains</term><term>Hypersensibilité médicamenteuse</term><term>Lymphoedème ()</term><term>Melphalan (effets indésirables)</term><term>Melphalan (usage thérapeutique)</term><term>Membres</term><term>Morbidité</term><term>Mâle</term><term>Mélanome (traitement médicamenteux)</term><term>Perfusion régionale de chimiothérapie anticancéreuse</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tumeurs cutanées (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Melphalan</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Lymphedema</term><term>Muscular Atrophy</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Melanoma</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Melphalan</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Melphalan</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Mélanome</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Melphalan</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Chemotherapy, Cancer, Regional Perfusion</term><term>Drug Hypersensitivity</term><term>Extremities</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Morbidity</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Amyotrophie</term><term>Femelle</term><term>Humains</term><term>Hypersensibilité médicamenteuse</term><term>Lymphoedème</term><term>Membres</term><term>Morbidité</term><term>Mâle</term><term>Perfusion régionale de chimiothérapie anticancéreuse</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To determine the influence of acute regional toxic reactions on the incidence and characteristics of long-term morbidity after regional isolated perfusion with melphalan.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7802575</PMID><DateCreated><Year>1995</Year><Month>01</Month><Day>26</Day></DateCreated><DateCompleted><Year>1995</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-0010</ISSN><JournalIssue CitedMedium="Print"><Volume>130</Volume><Issue>1</Issue><PubDate><Year>1995</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Archives of surgery (Chicago, Ill. : 1960)</Title><ISOAbbreviation>Arch Surg</ISOAbbreviation></Journal><ArticleTitle>Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions.</ArticleTitle><Pagination><MedlinePgn>43-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the influence of acute regional toxic reactions on the incidence and characteristics of long-term morbidity after regional isolated perfusion with melphalan.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">The Amsterdam and Rotterdam perfusion centers, the Netherlands.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">All patients with melanoma who were treated between 1978 and 1990 and had a minimum follow-up of 1 year after perfusion (n = 367).</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Fifty-four patients (15%) had perfusion of the upper limb, 313 (85%) had perfusion of the lower limb, and 164 patients (45%) underwent regional lymph node dissection at the time of perfusion.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Incidence and characteristics of morbidity 1 year after perfusion and the influence of acute regional toxic reactions on long-term morbidity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred sixty patients (44%) showed some degree of objective or subjective morbidity; most (104 [28%]) had lymphedema. Other long-term morbidity consisted of muscle atrophy or fibrosis (42 [11%]), limb malfunction (55 [15%]), neuropathy (13 [4%]), pain (28 [8%]), and recurrent infection (11 [3%]). Miscellaneous complications were seen in 14 patients (4%). Seventy-one patients (19%) had more than one complication. Acute regional toxic reactions had a statistically significant effect on the incidence of long-term morbidity (P < .01). Moderate to severe acute regional toxic reactions were strongly linked to the occurrence of muscle atrophy or fibrosis (P < .001) and limb malfunction (P < .001). Regional lymph node dissection was statistically significantly related to lymphedema (P = .05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Improvement of the perfusion technique should be pursued in an effort to reduce acute regional toxic reactions, and thereby long-term morbidity, without compromising the therapeutic effect.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vrouenraets</LastName><ForeName>B C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Surgery, The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Amsterdam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klaase</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Kroon</LastName><ForeName>B B</ForeName><Initials>BB</Initials></Author><Author ValidYN="Y"><LastName>van Geel</LastName><ForeName>B N</ForeName><Initials>BN</Initials></Author><Author ValidYN="Y"><LastName>Eggermont</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Franklin</LastName><ForeName>H R</ForeName><Initials>HR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Surg</MedlineTA><NlmUniqueID>9716528</NlmUniqueID><ISSNLinking>0004-0010</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>Q41OR9510P</RegistryNumber><NameOfSubstance UI="D008558">Melphalan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CitationSubset>S</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010478" MajorTopicYN="N">Chemotherapy, Cancer, Regional Perfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004342" MajorTopicYN="N">Drug Hypersensitivity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005121" MajorTopicYN="Y">Extremities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008558" MajorTopicYN="N">Melphalan</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009017" MajorTopicYN="N">Morbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009133" MajorTopicYN="N">Muscular Atrophy</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7802575</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Pays-Bas</li></country><region><li>Hollande-Septentrionale</li></region><settlement><li>Amsterdam</li></settlement></list><tree><noCountry><name sortKey="Eggermont, A M" sort="Eggermont, A M" uniqKey="Eggermont A" first="A M" last="Eggermont">A M Eggermont</name><name sortKey="Franklin, H R" sort="Franklin, H R" uniqKey="Franklin H" first="H R" last="Franklin">H R Franklin</name><name sortKey="Klaase, J M" sort="Klaase, J M" uniqKey="Klaase J" first="J M" last="Klaase">J M Klaase</name><name sortKey="Kroon, B B" sort="Kroon, B B" uniqKey="Kroon B" first="B B" last="Kroon">B B Kroon</name><name sortKey="Van Geel, B N" sort="Van Geel, B N" uniqKey="Van Geel B" first="B N" last="Van Geel">B N Van Geel</name></noCountry><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Vrouenraets, B C" sort="Vrouenraets, B C" uniqKey="Vrouenraets B" first="B C" last="Vrouenraets">B C Vrouenraets</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D00 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 004D00 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:7802575
|texte= Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:7802575" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |